DDInter350 DDInter1907
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with [methotrexate]. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients. In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. Ustekinumab is currently the first and only approved biologic therapy for ulcerative colitis that targets the interleukin (IL)-12 and IL-23 cytokines. The dosing regimen for ustekinumab is based on the patient's weight and there are intravenous and subcutaneous formulations of the drug based on the dosing schedule and condition being treated. Ustekinumab is commonly marketed under the trade name STELARA. Ustekinumab biosimilars are available in some markets, including Wezlana (ustekinumab-auub) in the US and Jamteki (AVT04) in Canada.
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Chlorambucil {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is treated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ustekinumab
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ustekinumab
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Olaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Chlorambucil {u} (Compound) binds {v} (Gene) SLCO1A2
SLCO1A2 {u} (Gene) is bound by {v} (Compound) Lovastatin
Lovastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Chlorambucil {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Eribulin
Eribulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mechlorethamine
Mechlorethamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Chlorambucil {u} (Compound) upregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is upregulated by {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Chlorambucil {u} (Compound) binds {v} (Gene) GSTP1
GSTP1 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ustekinumab
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Chlorambucil (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Chlorambucil (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Lovastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Chlorambucil (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Eribulin (Compound) and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Chlorambucil (Compound) upregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Chlorambucil (Compound) binds GSTP1 (Gene) and GSTP1 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab